GLPwatch
Papers (12034)
Page 122 of 201, ranked by citation count.
- Semaglutide for Weight Loss.
- Efficacy and safety of dulaglutide in patients with absolute insulin deficiency.
- Semaglutide use is associated with neuromuscular junction degradation in older adults with type II diabetes mellitus.
- Prevalence of normal coronary arteries by coronary computed tomography angiography (CCTA) in patients with type 2 diabetes mellitus from Semaglutide Treatment on Coronary Plaque Progression (STOP) trial.
- Ameliorative Impact of Liraglutide on Chronic Intermittent Hypoxia-Induced Atrial Remodeling.
- Real-world persistence and dose titration of GLP-1 receptor agonists in type 2 diabetes: A UK population-based cohort study by obesity and cardiovascular disease status.
- Impact of Incretin-Based Therapy on Skeletal Muscle Health.
- Pharmacologic Treatment of Obesity in adults and its impact on comorbidities: 2024 Update and Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM).
- Exenatide extended-release; clinical trials, patient preference, and economic considerations.
- Additive Effects of Exenatide, Glucose-insulin-potassium, and Remote Ischemic Conditioning Against Reperfusion Ventricular Arrhythmias in Pigs.
- Impact of Semaglutide Administration on Weight Loss After Bariatric Surgery: A Meta-Analysis.
- Targeting neuroinflammation in neurodegenerative disorders: the emerging potential of semaglutide.
- Combination therapies in the management of type 2 diabetes: the use of insulin degludec/liraglutide.
- Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients.
- Squalene-PEG-Exendin as High-Affinity Constructs for Pancreatic Beta-Cells.
- Cyclic Hydroxylamines for Native Residue-Forming Peptide Ligations: Synthesis of Ubiquitin and Tirzepatide.
- Exendin-4, a glucagon-like peptide-1 receptor agonist, regulates ductus arteriosus by vasodilation and anti-remodeling through the PKA pathway.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Reasons for discontinuing tirzepatide in randomized controlled trials: A systematic review and meta-analysis.
- PIONEER REAL Spain: A multicentre, prospective, real-world study of oral semaglutide use in adults with type 2 diabetes.
- Mechanism of and strategy to mitigate liraglutide-mediated positive chronotropy.
- Semaglutide in Cardiometabolic Diseases: SELECTing the Target Population.
- Peptide mapping analysis of synthetic semaglutide and liraglutide for generic development of drugs originating from recombinant DNA technology.
- Semaglutide reduces cardiovascular events in type 2 diabetes: a systematic review and meta-analysis highlighting enhanced benefits in chronic kidney disease.
- Dapagliflozin plus exenatide on patients with type 2 diabetes awaiting bariatric surgery in the DEXBASU study.
- Exploring the Impact of Semaglutide on Cognitive Function and Anxiety-Related Behaviors in a Murine Model of Alzheimer's Disease.
- Improved Glycaemic and Weight Management Are Associated with Better Quality of Life in People with Type 2 Diabetes Treated with Tirzepatide.
- UK regulator warns public after seizing hundreds of fake Ozempic pens.
- Orforglipron: A Novel Oral GLP-1 Agonist for the Treatment of Obesity and Diabetes.
- Optimizing weight control in diabetes: antidiabetic drug selection.
- De-intensification of basal-bolus therapy by replacing prandial insulin with once-weekly subcutaneous semaglutide in individuals with well-controlled type 2 diabetes: A single-centre, open-label randomised trial (TRANSITION-T2D).
- Oral Semaglutide: The First-available Noninjectable Glucagon-like Peptide 1 Receptor Agonist.
- Shared mechanistic pathways of glucagon signalling: Unlocking its potential for treating obesity, metabolic dysfunction-associated steatotic liver disease, and other cardio-kidney-metabolic conditions.
- Multi-omics analysis of hepatic outcomes in T2DM-MAFLD patients treated with semaglutide: a single-centre, longitudinal, data-driven study.
- Idiopathic intracranial hypertension: expanding our understanding.
- Effects of exendin-4 on colonic motility in rats and its underlying mechanism.
- Once weekly semaglutide and cardiovascular outcomes in patients with type 2 diabetes and heart failure with reduced left ventricular ejection fraction.
- Effects of six months treatment with liraglutide among patients with psoriasis and obesity, beyond metabolic control?
- Practice pearl: liraglutide and cardiovascular and renal events in type 2 diabetes.
- Letter to the Editor: Comment on Implications of Ozempic and Other Semaglutide Medications for Facial Plastic Surgeons.
- Exendin-4 shows no effects on the prostatic index in high-fat-diet-fed rat with benign prostatic hyperplasia by improving insulin resistance.
- Liraglutide for weight loss in obese people.
- GLP-1 Receptor Signaling and Oral Dysfunction: A Narrative Review on the Mechanistic Basis of Semaglutide-Related Oral Adverse Effects.
- Tirzepatide: unveiling a new dawn in dual-targeted diabetes and obesity management.
- Liraglutide as add-on therapy to insulin in type 2 diabetes mellitus: a retrospective, observational study from a daily clinical practice setting in Switzerland.
- Clinical outcomes of concomitant therapy of exenatide twice daily and basal insulin in patients with type 2 diabetes mellitus: a retrospective database analysis in the United States.
- Harnessing Facebook to Investigate Real-World Mentions of Adverse Events of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications: Observational Study of Facebook Posts From 2022 to 2024.
- Exenatide for obesity in children and adolescents: Systematic review and meta-analysis.
- [The pharmacological treatment of obesity: past, present and future].
- Minimizing Hypoglycemia and Weight Gain with Intensive Glucose Control: Potential Benefits of a New Combination Therapy (IDegLira).
- Tirzepatide-Induced Liver Injury: A Rare Medication Side Effect.
- iGlarLixi reduces residual hyperglycemia in Japanese patients with type 2 diabetes uncontrolled on basal insulin: A post-hoc analysis of the LixiLan JP-L trial.
- Comparative Meta-Analysis of Retatrutide Versus Placebo and Dulaglutide for Weight Loss and Diabetes Management: Insights From Clinical Trials.
- Exenatide improves cardiovascular risk factors in obese patients with type 2 diabetes mellitus: a prospective study
- Efficacy and safety of once-weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial.
- Impact of semaglutide on weight and functional outcomes among obese heart failure patients: a propensity scores matching analysis.
- Effect of Dual Glucagon-Like Peptide 1/Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist (Tirzepatide) versus Bariatric Surgery on Weight Loss and Nonalcoholic Fatty Liver Disease.
- Inhibition of exendin-4-induced steatosis by protein kinase A in cultured HepG2 human hepatoma cells.
- The pursuit of optimal semaglutide dosing in type 2 diabetes continues.
- Regulation of feeding and therapeutic application of bioactive peptides.